TERT gene fusions characterize a subset of metastatic Leydig cell tumors

Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was then followed by...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Bozo, Kruslin (author)
مؤلفون آخرون: Gatalica, Zoran (author), Hes, Ondrej (author), Skenderi, Faruk (author), Miettinen, Markku (author), Contreras, Elma (author), Xiu, Joanne (author), Elis, Michelle (author), Florento, Elena (author), Vranic, Semir (author), Swensen, Jeffrey (author)
التنسيق: article
منشور في: 2021
الموضوعات:
الوصول للمادة أونلاين:http://dx.doi.org/10.1016/j.clgc.2021.02.002
https://www.sciencedirect.com/science/article/pii/S155876732100046X?v=s5
http://hdl.handle.net/10576/17834
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1857415085816807424
author Bozo, Kruslin
author2 Gatalica, Zoran
Hes, Ondrej
Skenderi, Faruk
Miettinen, Markku
Contreras, Elma
Xiu, Joanne
Elis, Michelle
Florento, Elena
Vranic, Semir
Swensen, Jeffrey
author2_role author
author
author
author
author
author
author
author
author
author
author_facet Bozo, Kruslin
Gatalica, Zoran
Hes, Ondrej
Skenderi, Faruk
Miettinen, Markku
Contreras, Elma
Xiu, Joanne
Elis, Michelle
Florento, Elena
Vranic, Semir
Swensen, Jeffrey
author_role author
dc.creator.none.fl_str_mv Bozo, Kruslin
Gatalica, Zoran
Hes, Ondrej
Skenderi, Faruk
Miettinen, Markku
Contreras, Elma
Xiu, Joanne
Elis, Michelle
Florento, Elena
Vranic, Semir
Swensen, Jeffrey
dc.date.none.fl_str_mv 2021-03-01T08:04:15Z
2021-02-18
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://dx.doi.org/10.1016/j.clgc.2021.02.002
Bozo Kruslin , Zoran Gatalica , Ondrej Hes , Faruk Skenderi , Markku Miettinen , Elma Contreras , Joanne Xiu , Michelle Elis , Elena Florento , Semir Vranic , Jeffrey Swensen , TERT gene fusions characterize a subset of metastatic Leydig cell tumors, Clinical Genitourinary Cancer (2021), doi: https://doi.org/10.1016/j.clgc.2021.02.002
15587673
https://www.sciencedirect.com/science/article/pii/S155876732100046X?v=s5
http://hdl.handle.net/10576/17834
dc.language.none.fl_str_mv en
dc.publisher.none.fl_str_mv Elsevier
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Sex cord–stromal tumors
Leydig cell tumor
molecular profiling
sequencing
targeted therapy
dc.title.none.fl_str_mv TERT gene fusions characterize a subset of metastatic Leydig cell tumors
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Objective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was then followed by an investigation into a cohort of additional LCTs. Patients and Methods: Twenty-nine LCT (27 male and 2 female patients) were profiled using NGS and immunohistochemistry. Results: TERT gene fusions were detected only in testicular metastatic Leydig cell tumors, in three of seven successfully analyzed cases (RMST:TERT, LDLR:TERT and B4GALT5:TERT). TOP1 and CCND3 amplifications were identified in the case with a B4GALT5:TERT fusion. A TP53 mutation was detected in one metastatic tumor without a TERT fusion. Five primary (four testicular and one ovarian) LCTs showed multiple gene amplifications, without a consistent pattern. A single metastatic ovarian LCT showed BAP1 mutation and copy number amplifications affecting the NPM1, PCM1 and SS18 genes. At the protein level, 4/7 metastatic and 6/10 primary testicular LCTs over-expressed TOP1. Androgen receptor (AR) was overexpressed in 10/13 primary testicular tumors and 2/5 metastatic testicular LCT (without detectable ARv7 mRNA or ARv7 protein). Only one metastatic testicular LCT exhibited high TMB while all tested cases were MSI stable and did not express PD-L1. Conclusions: Our study for the first time identified TERT gene fusions as a main genetic alteration and a potential therapeutic target in metastatic Leydig cell tumors. TOP1 and AR may guide decisions on chemo- and/or hormone therapy for selected individual patients.
eu_rights_str_mv openAccess
format article
id qu_87e98615ec9d8a6cd34172fc2ed1ae55
identifier_str_mv Bozo Kruslin , Zoran Gatalica , Ondrej Hes , Faruk Skenderi , Markku Miettinen , Elma Contreras , Joanne Xiu , Michelle Elis , Elena Florento , Semir Vranic , Jeffrey Swensen , TERT gene fusions characterize a subset of metastatic Leydig cell tumors, Clinical Genitourinary Cancer (2021), doi: https://doi.org/10.1016/j.clgc.2021.02.002
15587673
language_invalid_str_mv en
network_acronym_str qu
network_name_str Qatar University repository
oai_identifier_str oai:qspace.qu.edu.qa:10576/17834
publishDate 2021
publisher.none.fl_str_mv Elsevier
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
spelling TERT gene fusions characterize a subset of metastatic Leydig cell tumorsBozo, KruslinGatalica, ZoranHes, OndrejSkenderi, FarukMiettinen, MarkkuContreras, ElmaXiu, JoanneElis, MichelleFlorento, ElenaVranic, SemirSwensen, JeffreySex cord–stromal tumorsLeydig cell tumormolecular profilingsequencingtargeted therapyObjective: Metastatic Leydig cell tumors (LCT) are rare, difficult to treat malignancies without known underlying molecular-genetic events. An index case of metastatic LCT showed an LDLR-TERT gene fusion upon routine genetic profiling for detection of therapeutic targets, which was then followed by an investigation into a cohort of additional LCTs. Patients and Methods: Twenty-nine LCT (27 male and 2 female patients) were profiled using NGS and immunohistochemistry. Results: TERT gene fusions were detected only in testicular metastatic Leydig cell tumors, in three of seven successfully analyzed cases (RMST:TERT, LDLR:TERT and B4GALT5:TERT). TOP1 and CCND3 amplifications were identified in the case with a B4GALT5:TERT fusion. A TP53 mutation was detected in one metastatic tumor without a TERT fusion. Five primary (four testicular and one ovarian) LCTs showed multiple gene amplifications, without a consistent pattern. A single metastatic ovarian LCT showed BAP1 mutation and copy number amplifications affecting the NPM1, PCM1 and SS18 genes. At the protein level, 4/7 metastatic and 6/10 primary testicular LCTs over-expressed TOP1. Androgen receptor (AR) was overexpressed in 10/13 primary testicular tumors and 2/5 metastatic testicular LCT (without detectable ARv7 mRNA or ARv7 protein). Only one metastatic testicular LCT exhibited high TMB while all tested cases were MSI stable and did not express PD-L1. Conclusions: Our study for the first time identified TERT gene fusions as a main genetic alteration and a potential therapeutic target in metastatic Leydig cell tumors. TOP1 and AR may guide decisions on chemo- and/or hormone therapy for selected individual patients.Qatar National LibraryElsevier2021-03-01T08:04:15Z2021-02-18Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://dx.doi.org/10.1016/j.clgc.2021.02.002Bozo Kruslin , Zoran Gatalica , Ondrej Hes , Faruk Skenderi , Markku Miettinen , Elma Contreras , Joanne Xiu , Michelle Elis , Elena Florento , Semir Vranic , Jeffrey Swensen , TERT gene fusions characterize a subset of metastatic Leydig cell tumors, Clinical Genitourinary Cancer (2021), doi: https://doi.org/10.1016/j.clgc.2021.02.00215587673https://www.sciencedirect.com/science/article/pii/S155876732100046X?v=s5http://hdl.handle.net/10576/17834enhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:qspace.qu.edu.qa:10576/178342024-07-23T11:23:28Z
spellingShingle TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Bozo, Kruslin
Sex cord–stromal tumors
Leydig cell tumor
molecular profiling
sequencing
targeted therapy
status_str publishedVersion
title TERT gene fusions characterize a subset of metastatic Leydig cell tumors
title_full TERT gene fusions characterize a subset of metastatic Leydig cell tumors
title_fullStr TERT gene fusions characterize a subset of metastatic Leydig cell tumors
title_full_unstemmed TERT gene fusions characterize a subset of metastatic Leydig cell tumors
title_short TERT gene fusions characterize a subset of metastatic Leydig cell tumors
title_sort TERT gene fusions characterize a subset of metastatic Leydig cell tumors
topic Sex cord–stromal tumors
Leydig cell tumor
molecular profiling
sequencing
targeted therapy
url http://dx.doi.org/10.1016/j.clgc.2021.02.002
https://www.sciencedirect.com/science/article/pii/S155876732100046X?v=s5
http://hdl.handle.net/10576/17834